Some noteworthy PSGs include dihydroergotamine mesylate nasal spray, glucagon nasal powder, afamelanotide subcutaneous implant, and triamcinolone acetonide injectable suspension.
On Feb. 16 2023, FDA published a new set of product-specific guidance documents that provide recommendations for developing generic drugs and creates evidence to support abbreviated new drug application (ANDA) approvals, which helps to streamline generic product and ANDA assessment.
The FDA publishes PSGs to help facilitate generic drug competition, supporting greater access to safe, effective, and potentially lower-cost treatments. Additionally, improving access to high-quality, affordable medicines helps the agency’s mission to advance public health.
The recent group of 30 PSGs includes:
Some noteworthy PSGs include dihydroergotamine mesylate nasal spray, glucagon nasal powder, afamelanotide subcutaneous implant, and triamcinolone acetonide injectable suspension.
The FDA also updated their “Upcoming Product-Specific Guidances for Generic Drug Product Development” website to include PSG revision categories and brief descriptions of the revisions that will help applicants in determining if a PSG revision may impact their generic drug development program.
Source: FDA
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.